Market research
ATQP.F Vericel Corporation
F EUR Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 2B
- P/E ratio
- 79.02
- Analyst target
- 65.04
- Dividend yield
- Not available
- Beta
- 1.05
Profile
Company facts
- Exchange
- F
- Currency
- EUR
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- US92346J1088
- Market cap
- 2B
- P/E ratio
- 79.02
- Analyst target
- 65.04
- Dividend yield
- Not available
- Beta
- 1.05
About
About Vericel Corporation
Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies and specialty biologic products for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults and pediatric patients with deep partial-thickness and/or full-thickness thermal burns. Vericel Corporation was formerly known as Aastrom Biosciences, Inc. and changed its name to Vericel Corporation in November 2014. The company was incorporated in 1989 and is headquartered in Burlington, Massachusetts.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the ATQP.F discussion.
5 years, 5 months ago
Vericel Corporation is currently in a long term uptrend where the price is trading 34.2% above its 200 day moving average.
From a valuation standpoint, the stock is 98.4% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 21.1.
Vericel Corporation's total revenue rose by 14.8% to $45M since the same quarter in the previous year.
Its net income has increased by 28.6% to $12M since the same quarter in the previous year.
Finally, its free cash flow grew by 268.1% to $10M since the same quarter in the previous year.
Based on the above factors, Vericel Corporation gets an overall score of 5/5.